Texas Settles Vyvanse Medicaid Fraud Allegations With Takeda, Baxter for $42 Million

Texas has settled with Takeda Pharmaceuticals and Baxter International for $42 million over allegations the companies provided kickbacks to Medicaid providers to recommend prescription medications including the attention deficit hyperactivity…

Continue ReadingTexas Settles Vyvanse Medicaid Fraud Allegations With Takeda, Baxter for $42 Million

Industry Objects to “Stacking” Requirement in Medicaid Drug Rebate Rule

The big three drug associations, representing brand pharmaceuticals, generics and biotechnology, have all expressed strong objections to the CMS proposed rule for the Medicaid Drug Rebate program “stacking” requirement that…

Continue ReadingIndustry Objects to “Stacking” Requirement in Medicaid Drug Rebate Rule

Social Anxiety Disorder Responds to Vistagen’s Nasal Spray in Phase 3 Trial

Vistagen’s fasedienol (PH94B) nasal spray for social anxiety disorder (SAD) showed a statistically significant reduction in anxiety measures during a public speaking challenge, using a measure of subjective units of…

Continue ReadingSocial Anxiety Disorder Responds to Vistagen’s Nasal Spray in Phase 3 Trial